Halyard Health, Inc. (HYH) Trades at $46.83 After Triangle; Shorts at SOSEI CO LTD TOKYO ORDINARY SHARES JAPA (SOLTF) Lowered By 1.89%

Halyard Health, Inc. (NYSE:HYH) Logo

Halyard Health, Inc. (HYH) formed triangle with $49.17 target or 5.00% above today’s $46.83 share price. Halyard Health, Inc. (HYH) has $2.20B valuation. The stock increased 1.06% or $0.49 during the last trading session, reaching $46.83. About 290,449 shares traded. Halyard Health, Inc. (NYSE:HYH) has risen 20.55% since April 30, 2017 and is uptrending. It has outperformed by 9.00% the S&P500.

SOSEI CO LTD TOKYO ORDINARY SHARES JAPA (OTCMKTS:SOLTF) had a decrease of 1.89% in short interest. SOLTF’s SI was 436,100 shares in April as released by FINRA. Its down 1.89% from 444,500 shares previously. With 100 avg volume, 4361 days are for SOSEI CO LTD TOKYO ORDINARY SHARES JAPA (OTCMKTS:SOLTF)’s short sellers to cover SOLTF’s short positions. It closed at $84.75 lastly. It is down 0.00% since April 30, 2017 and is . It has underperformed by 11.55% the S&P500.

Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. The company has market cap of $1.29 billion. The Company’s marketed products include Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease ; Ultibro/QVA149, an inhalation capsule for the bronchodilator treatment of COPD; and NorLevo, an oral emergency contraceptive. It currently has negative earnings. The companyÂ’s product pipeline consists of SO-1105, an antifungal agent, which is in Phase III clinical trial for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are in pre-clinical stage for infectious eye diseases, such as cornea and conjunctivitis, and inflammation.

Among 7 analysts covering Halyard Health Inc (NYSE:HYH), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Halyard Health Inc had 19 analyst reports since July 21, 2015 according to SRatingsIntel. Raymond James initiated the shares of HYH in report on Tuesday, July 21 with “Market Perform” rating. The rating was downgraded by JMP Securities on Friday, January 6 to “Mkt Perform”. Stifel Nicolaus maintained it with “Buy” rating and $4500 target in Wednesday, August 2 report. The stock of Halyard Health, Inc. (NYSE:HYH) earned “Buy” rating by Stifel Nicolaus on Wednesday, December 2. On Friday, April 8 the stock rating was initiated by Stephens with “Overweight”. The stock of Halyard Health, Inc. (NYSE:HYH) earned “Hold” rating by KeyBanc Capital Markets on Tuesday, October 17. Stifel Nicolaus maintained Halyard Health, Inc. (NYSE:HYH) on Tuesday, June 14 with “Buy” rating. Stephens upgraded Halyard Health, Inc. (NYSE:HYH) on Thursday, August 3 to “Overweight” rating. The company was maintained on Thursday, August 3 by Deutsche Bank. The stock of Halyard Health, Inc. (NYSE:HYH) earned “Buy” rating by Stifel Nicolaus on Wednesday, January 27.

Analysts await Halyard Health, Inc. (NYSE:HYH) to report earnings on May, 1. They expect $-0.04 earnings per share, down 108.33% or $0.52 from last year’s $0.48 per share. After $0.73 actual earnings per share reported by Halyard Health, Inc. for the previous quarter, Wall Street now forecasts -105.48% negative EPS growth.